Assessment of neuronal activity using iPSC-derived human neurons and microelectrode array:

  • The eCiphr®Neuro assay uses FUJIFILM Cellular Dynamics, Inc. (FCDI) human iPSC-derived glutamatergic neurons co-cultured with human iPSC-derived astrocytes.
  • Cyprotex’s neuronal assay uses high throughput microelectrode array (MEA) technology to monitor electrophysiological activity.
  • Neurons grown on microelectrode arrays recapitulate many features of neurons in vivo, including spontaneous activity (spiking and bursting), plasticity, organization and responsiveness to a wide range of neurotransmitters and pharmacological agonists/antagonists1,2.
  • This technology provides a unique in vitro system for preclinical drug discovery, neurotoxicity assessment and disease modelling.


eCiphr®Neuro-Human Assay Protocol


Data from Cyprotex's eCiphr®Neuro-Human Assay


1) Robinette BL et al, (2011). In vitro assessment of developmental neurotoxicity: use of microelectrode arrays to measure functional changes in neuronal network ontogeny. Front Neuroeng 4; Article 1
2) Bradley JA et al, (2018). In vitro screening for seizure liability using microelectrode array technology. Tox Sci 163(1); 240-253


Cyprotex eStore

Order our services online.

Visit the Cyprotex eStore

Contact Our Experts

Paul Walker

Paul Walker, PhD

VP Head of Toxicology & Innovation Efficiency

Logo Cyprotex white
Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. By combining quality data from robust in vitro methods with contemporary in silico technology, we add value, context and relevance to the ADME-Tox data supplied to our partners in the pharmaceutical or chemical industries.